首页> 外文期刊>转化神经科学电子杂志(英文) >Xenopus transgenic to screen candidate molecules favoring myelin repair
【24h】

Xenopus transgenic to screen candidate molecules favoring myelin repair

机译:爪蟾转基因以筛选有利于髓鞘修复的候选分子

获取原文
获取原文并翻译 | 示例
           

摘要

To facilitate live imaging of demyelination and remyelination, we have generated a Xenopus laevis transgenic line, MBP-GFP-NTR, allowing conditional ablation of myelinating oligodendrocytes. In this line, the proximal portion of mouse myelin basic protein (MBP) regulatory sequence, specific to mature myelin-forming oligodendrocytes, drives the expression of a transgene protein formed by the GFP reporter fused to the Escherichia coli nitroreductase (NTR) selection enzyme. The NTR enzyme converts the innocuous prodrug metronidazole (MTZ) to a cytotoxin. The demyelination response of MBP-GFP-NTR tadpoles to MTZ is followed by spontaneous remyelination after cessation of MTZ treatment. Thanks to the transparency of tadpoles, these events can be monitored in vivo by two-photon imaging and easily quantified on a simple fluorescence macroscope. We have used the MBP-GFP-NTR model to screen in vivo molecules favoring remyelination. At the end of MTZ-induced demyelination, tadpoles were switched to water containing the compounds to be tested. After 3 days of treatment remyelination was assayed by counting the number of GFP+ oligodendrocytes per optic nerve. Using Crispr/Cas9 strategy, the target of the candidate molecule can be easily deleted in the MBPGFP-NTR line to examine the mechanism of action of the candidate molecule. Therefore the Xenopus laevis transgenic line, MBP-GFP-NTR, allowing conditional ablation of myelinating oligodendrocytes, constitutes a new medium-throughput screening platform for myelin repair therapeutics in demyelinating diseases.
机译:为了促进脱髓鞘和再髓鞘的实时成像,我们产生了非洲爪蟾转基因株系MBP-GFP-NTR,可以有条件地消融髓鞘少突胶质细胞。在这条线中,对成熟的形成髓鞘的少突胶质细胞特异的小鼠髓鞘碱性蛋白(MBP)调节序列的近端部分驱动由GFP报告基因与大肠杆菌硝化还原酶(NTR)选择酶融合的转基因蛋白的表达。 NTR酶将无毒的前药甲硝唑(MTZ)转化为细胞毒素。 MBP-GFP-NTR to对MTZ的脱髓鞘反应继之以停止MTZ治疗后的自发性髓鞘再生。由于of的透明性,这些事件可以通过双光子成像在体内进行监测,并可以在简单的荧光显微镜下轻松量化。我们已经使用MBP-GFP-NTR模型来筛选有利于髓鞘再生的体内分子。在MTZ诱导的脱髓鞘作用结束时,将t换成含有待测化合物的水。治疗3天后,通过计数每个视神经的GFP +少突胶质细胞的数量来测定髓鞘再生。使用Crispr / Cas9策略,可以在MBPGFP-NTR品系中轻松删除候选分子的靶标,以检查候选分子的作用机理。因此,非洲爪蟾的转基因株系MBP-GFP-NTR允许条件性切除髓鞘少突胶质细胞,构成了用于髓鞘病脱髓鞘修复疗法的新型中通量筛选平台。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号